Insulin resistance, hepatic steatosis and hepatitis C: A complex relationship with relevant clinical implications

Annals of Hepatology

Volumn 9, Issue SUPPL. 1, 2010, Pages 112-118

  Arrese, Marco ^a   Riquelme, Arnoldo ^a   Soza, Alejandro ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Diabetes; Fatty liver; Insulin; Metabolic syndrome

Indexed keywords

GLUCOSE TRANSPORTER 4; INSULIN RECEPTOR SUBSTRATE; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 1; METFORMIN; PIOGLITAZONE; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR ALPHA; ANTIDIABETIC AGENT; ANTIVIRUS AGENT;

ARTICLE; DISEASE COURSE; DISEASE SEVERITY; ENZYME ACTIVATION; FATTY LIVER; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE UTILIZATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; LIFESTYLE; LIPOGENESIS; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; RISK FACTOR; SIGNAL TRANSDUCTION; CALORIC INTAKE; METABOLISM; PATHOPHYSIOLOGY; REVIEW; RISK REDUCTION; TREATMENT OUTCOME; VIRUS LOAD; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; ENERGY INTAKE; FATTY LIVER; HEPATITIS C; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME; VIRAL LOAD; WEIGHT LOSS;

EID: 79952111965     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31735-1     Document Type: Article

References (58)

1. Bloomgarden ZT. Insulin resistance concepts. Diabetes Care 2007; 30: 1320-1326.
2. Reaven GM. The insulin resistance syndrome: Definition and dietary approaches to treatment. Annu Rev Nutr 2005; 25: 391-406.
3. Méndez-Sánchez N, Arrese M, Zamora-Valdés D, Uribe M. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int 2007; 27: 423-433.
4. Méndez-Sánchez N, Chávez-Tapia NC, Zamora-Valdés D, Medina-Santillan R, Uribe M. Hepatobiliary diseases and insulin resistance. Curr Med Chem 2007;14:1988-1999.
5. Machado MV, Cortez-Pinto H. Insulin resistance and steatosis in chronic hepatitis C. Ann Hepatol 2009; 8: S67-S75.
6. Harrison SA. Insulin resistance among patients with chronic hepatitis C: Etiology and impact on treatment. Clin Gastroenterol Hepatol 2008; 6: 864-876.
7. Romero-Gómez M. Insulin resistance and hepatitis C. World J Gastroenterol 2006; 12: 7075-7080.
8. Del Campo JA, Romero-Gómez M. Steatosis and insulin resistance in hepatitis C: a way out for the virus? World J Gastroenterol 2009; 15: 5014-5019.
9. Douglas MW, George J. Molecular mechanisms of insulin resistance in chronic hepatitis C. World J Gastroenterol 2009; 15: 4356-4364.
10. Serfaty L, Capeau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int 2009; 29: S2,13-25.
11. Patel JH, Cobbold JF, Thomas HC, Taylor-Robinson SD. Hepatitis C and hepatic steatosis. QJM 2010; 103(5): 293-303.
12. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003; 125: 1695-1704.
13. Bernsmeier C, Heim MH. Insulin resistance in chronic hepatitis C: Mechanisms and clinical relevance. Swiss Med Wkly 2009; 139: 678-684.
14. Milner KL, Van der Poorten D, Trenell M, Jenkins AB, Xu A, Smythe G, Dore GJ, et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 2010; 138(3): 931-941.
15. Negro F, Alaei M. Hepatitis C virus and type 2 diabetes. World J Gastroenterol 2009; 15: 1537-1547.
16. Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J, Szklo M, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003; 38: 50-56.
17. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: A systematic review and meta-analysis. J Hepatol 2008; 49: 831-844.
18. Blonsky JJ, Harrison SA. Review article: Non-alcoholic fatty liver disease and hepatitis C virus-partners in crime. Aliment Pharmacol Ther 2008; 27: 855-865.
19. Negro F, Clement S. Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. J Viral Hepat 2009; 16: 681-688.
20. Reaven GM. The insulin resistance syndrome: Concept and therapeutic approaches. In: Mogensen CE (Ed.). Pharmacotherapy of diabetes: New developments. improving life and prognosis for diabetic patients. New York: Springer US; 2007, p. 19-30.
21. Muoio DM, Newgard CB. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and betacell failure in type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9: 193-205.
22. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Moriya K, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-848.
23. Cua IH, Hui JM, Bandara P, Kench JG, Farrell GC, McCaughan GW, George J. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 2007; 46: 66-73.
24. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
25. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140.
26. Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006; 91: 4753-4761.
27. Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity. Biochim Biophys Acta 2010: 1801(3): 299-310.
28. Arrese M, Karpen SJ. Nuclear receptors, inflammation and liver disease: Insights for cholestatic and fatty liver diseases. Clin Pharmacol Ther 2010; 87(4): 473-478.
29. Ramesh S, Sanyal AJ. Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis 2004; 24: 399-413.
30. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.
31. Romero-Gómez M. Hepatitis C and insulin resistance: steatosis, fibrosis and non-response. Rev Esp Enferm Dig 2006; 98: 605-615.
32. Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005; 41: 82-87.
33. Romero-Gómez M, Del Mar VM, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-641.
34. Chu CJ, Lee SD, Hung TH, Lin HC, Hwang SJ, Lee FY, Lu RH, et al. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin. Aliment Pharmacol Ther 2009; 29: 46-54.
35. Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, Wahed AS. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007; 45: 80-87.
36. Dai CY, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Wang LY, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009; 50: 712-718.
37. Moucari R, Ripault MP, Martinot-Peignoux M, Voitot H, Cardoso AC, Stern C, Boyer N, et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009; 58: 1662-1669.
38. Poustchi H, Negro F, Hui J, Cua IH, Brandt LR, Kench JG, George J. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008; 48: 28-34.
39. Muzzi A, Leandro G, Rubbia-Brandt L, James R, Keiser O, Malinverni R, Dufour JF, et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005; 42: 41-46.
40. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005; 100: 1509-1515.
41. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, Adinolfi LE, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-1642.
42. Castera L, Chouteau P, Hezode C, Zafrani ES, Dhumeaux D, Pawlotsky JM. Hepatitis C virus-induced hepatocellular steatosis. Am J Gastroenterol 2005; 100: 711-715.
43. Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, et al. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010;138(1):136-146.
44. Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, Chung RT, Bonkovsky HL, et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 2009; 137: 549-557.
45. Negro F. Steatosis in chronic hepatitis C: friend or foe? Liver Int 2008; 28: 294-296.
46. Wang CS, Yao WJ, Chang TT, Wang ST, Chou P. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses. Cancer Epidemiol Biomarkers Prev 2009; 18: 2054-2060.
47. Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, De Knegt RJ, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008; 47: 1856-1862.
48. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009; 49: 739-744.
49. Hickman IJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S, Jonsson JR, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51: 89-94.
50. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, Powell EE. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53: 413-419.
51. Tarantino G, Conca P, Ariello M, Mastrolia M. Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis? Gut 2006; 55: 585.
52. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
53. Overbeck K, Genne D, Golay A, Negro F. Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. J Hepatol 2008; 49: 295-298.
54. Elgouhari HM, Cesario KB, López R, Zein NN. Pioglitazone improves early virologic kinetic response to PEG IFN/RBV combination therapy in hepatitis C genotype 1 naýve patients. Hepatology 2008; 48: 383A.
55. Conjeevaram H, Burant CF, McKenna B, Harsh D, Kang H, Das AK, Everett L, et al. A randomized, double-blind, placebo-controlled study of PPARgamma agonist pioglitazone given in combination with peginterferon and ribavirin in patients with genotype-1 chronic hepatitis C. Hepatology 2008; 48: 384A.
56. Khattab M, Emad M, Abdelaleem A, Eslam M, Atef R, Shaker Y, Hamdy L. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int 2010; 30(3): 447-454.
57. Serfaty L, Fartoux L, Poupon R. Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin? J Hepatol 2009; 50: 1269-1271.
58. Romero-Gómez M, Diago M, Andrade RJ, Calleja JL, Salmeron J, Fernández-Rodríguez CM, Sola R, et al. Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009; 50: 1702-1708.